{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:09:04Z","timestamp":1792807744377,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40263-024-01071-6","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T18:01:57Z","timestamp":1708711317000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-160X","authenticated-orcid":false,"given":"Senta","family":"Frol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja Pretnar","family":"Oblak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u0161o","family":"\u0160abovi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Kermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"issue":"14","key":"1071_CR1","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, ANNEXA-4 Investigators, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"1071_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2396987319849763","volume":"4","author":"H Christensen","year":"2019","unstructured":"Christensen H, Cordonnier C, K\u00f5rv J, et al. European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J. 2019;4(4):294\u2013306.","journal-title":"Eur Stroke J"},{"issue":"10","key":"1071_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, External reviewers, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612\u201376.","journal-title":"Europace"},{"issue":"7","key":"1071_CR4","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","volume":"53","author":"SM Greenberg","year":"2022","unstructured":"Greenberg SM, Ziai WC, Cordonnier C, American Heart Association\/American Stroke Association, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2022;53(7):e282-361. https:\/\/doi.org\/10.1161\/STR.0000000000000407.","journal-title":"Stroke"},{"issue":"6","key":"1071_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40263-023-01006-7","volume":"37","author":"S Frol","year":"2023","unstructured":"Frol S, Oblak JP, \u0160abovi\u010d M, et al. Andexanet alfa to reverse the effect of factor Xa inhibitors in intracranial hemorrhage. CNS Drugs. 2023;37(6):477\u201387. https:\/\/doi.org\/10.1007\/s40263-023-01006-7.","journal-title":"CNS Drugs"},{"issue":"6","key":"1071_CR6","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1161\/STROKEAHA","volume":"52","author":"AM Demchuk","year":"2021","unstructured":"Demchuk AM, Yue P, Zotova E, ANNEXA-4 Investigators, et al. Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy. Stroke. 2021;52(6):2096\u2013105. https:\/\/doi.org\/10.1161\/STROKEAHA.","journal-title":"Stroke"},{"issue":"2","key":"1071_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/MCC.0000000000000706","volume":"26","author":"M Strein","year":"2020","unstructured":"Strein M, May S, Brophy GM. Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants. Curr Opin Crit Care. 2020;26(2):122\u20138. https:\/\/doi.org\/10.1097\/MCC.0000000000000706.","journal-title":"Curr Opin Crit Care"},{"issue":"13","key":"1071_CR8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","volume":"147","author":"TJ Milling Jr","year":"2023","unstructured":"Milling TJ Jr, Middeldorp S, Xu L, ANNEXA-4 Investigators, et al. Final study report of andexanet alfa for major bleeding with Factor Xa inhibitors. Circulation. 2023;147(13):1026\u201338. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057844.","journal-title":"Circulation"},{"key":"1071_CR9","doi-asserted-by":"publisher","DOI":"10.5551\/jat.64223","author":"K Toyoda","year":"2023","unstructured":"Toyoda K, Arakawa S, Ezura M, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity: prespecified subgroup analysis of the ANNEXA-4 study in Japan. J Atheroscler Thromb. 2023. https:\/\/doi.org\/10.5551\/jat.64223.","journal-title":"J Atheroscler Thromb"},{"key":"1071_CR10","unstructured":"Connolly SJ. Randomized trial of andexanet alfa versus usual care in patients with acute intracranial hemorrhage while on an oral factor Xa inhibitor: ANNEXa-I [presentation]. In: Presented at the World Stroke Congress (WSC); 10\u201312 October, 2023; Toronto (ON)."},{"issue":"1","key":"1071_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","volume":"56","author":"SS Sutton","year":"2023","unstructured":"Sutton SS, Magagnoli J, Cummings TH, et al. Real-world clinical outcomes among US veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate. J Thromb Thrombolysis. 2023;56(1):137\u201346. https:\/\/doi.org\/10.1007\/s11239-023-02820-y. (Epub 2023 May 23. Erratum in: J Thromb Thrombolysis. 2023 Jun 12).","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"1071_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11239-022-02715-4","volume":"55","author":"C Troyer","year":"2023","unstructured":"Troyer C, Nguyen W, Xie A, et al. Retrospective review of andexanet alfa versus 4-factor prothrombin complex concentrate for reversal of DOAC-associated intracranial hemorrhage. J Thromb Thrombolysis. 2023;55(1):149\u201355. https:\/\/doi.org\/10.1007\/s11239-022-02715-4.","journal-title":"J Thromb Thrombolysis"},{"key":"1071_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107621","volume":"226","author":"AA Ammar","year":"2023","unstructured":"Ammar AA, Elsamadicy AA, Ammar MA, et al. Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa. Clin Neurol Neurosurg. 2023;226: 107621. https:\/\/doi.org\/10.1016\/j.clineuro.2023.107621.","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"1071_CR14","doi-asserted-by":"publisher","first-page":"102192","DOI":"10.1016\/j.rpth.2023.102192","volume":"7","author":"PP Dobesh","year":"2023","unstructured":"Dobesh PP, Fermann GJ, Christoph MJ, et al. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study. Res Pract Thromb Haemost. 2023;7(6):102192. https:\/\/doi.org\/10.1016\/j.rpth.2023.102192.","journal-title":"Res Pract Thromb Haemost."},{"issue":"5","key":"1071_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/MEJ.0000000000001049","volume":"30","author":"B Backus","year":"2023","unstructured":"Backus B, Beyer-Westendorf J, Body R, et al. Management of major bleeding for anticoagulated patients in the emergency department: an European experts consensus statement. Eur J Emerg Med. 2023;30(5):315\u201323. https:\/\/doi.org\/10.1097\/MEJ.0000000000001049.","journal-title":"Eur J Emerg Med"},{"issue":"233","key":"1071_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107908","volume":"20","author":"JE Orban 3rd","year":"2023","unstructured":"Orban JE 3rd, Ruckel C, Harlan S. Concomitant andexanet alfa and 4 F-PCC for factor Xa inhibitor associated intracranial hemorrhage. Clin Neurol Neurosurg. 2023;20(233): 107908. https:\/\/doi.org\/10.1016\/j.clineuro.2023.107908.","journal-title":"Clin Neurol Neurosurg"},{"issue":"31","key":"1071_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2023.e01710","volume":"13","author":"G Wahbah Makhoul","year":"2023","unstructured":"Wahbah Makhoul G, Mustafa A, Ling J, et al. Lactococcus endocarditis after Bentall procedure presenting with intracranial hemorrhage. IDCases. 2023;13(31): e01710. https:\/\/doi.org\/10.1016\/j.idcr.2023.e01710.","journal-title":"IDCases."},{"key":"1071_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad215","author":"D Jenniches","year":"2023","unstructured":"Jenniches D, Kerns AF, DelBianco J, et al. Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: a case report. Am J Health Syst Pharm. 2023. https:\/\/doi.org\/10.1093\/ajhp\/zxad215.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1071_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/fca-2020-0073","volume":"17","author":"CI Coleman","year":"2021","unstructured":"Coleman CI, Dobesh PP, Danese S, et al. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. Future Cardiol. 2021;17(1):127\u201335. https:\/\/doi.org\/10.2217\/fca-2020-0073.","journal-title":"Future Cardiol"},{"key":"1071_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106070","volume":"195","author":"A Giovino","year":"2020","unstructured":"Giovino A, Shomo E, Busey KV, et al. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Clin Neurol Neurosurg. 2020;195: 106070. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106070.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"1071_CR21","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1002\/ajh.25326","volume":"94","author":"SE Culbreth","year":"2019","unstructured":"Culbreth SE, Rimsans J, Sylvester K, et al. Andexanet alfa: the first 150 days. Am J Hematol. 2019;94(1):E21\u20134. https:\/\/doi.org\/10.1002\/ajh.25326.","journal-title":"Am J Hematol"},{"issue":"14","key":"1071_CR22","doi-asserted-by":"publisher","first-page":"1126958","DOI":"10.3389\/fneur.2023.1126958","volume":"16","author":"JJ Ratcliff","year":"2023","unstructured":"Ratcliff JJ, Hall AJ, Porto E, et al. Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): study protocol for a multi-centered two-arm randomized adaptive trial. Front Neurol. 2023;16(14):1126958. https:\/\/doi.org\/10.3389\/fneur.2023.1126958.","journal-title":"Front Neurol"},{"key":"1071_CR23","unstructured":"Hall AJ, Ratcliff JJ, Porto E, et al. Very early minimally invasive removal of intracerebral hemorrhage: the ENIRCH trial [press release]. In: Presented at the European Stroke Organisation Conference; 25 May, 2023; Munich."},{"key":"1071_CR24","unstructured":"Hall A, Ratcliff JJ.\u00a0ENRICH trial: early surgical intervention in intracerebral hemorrhage\u00a0[interview with VJNeurology]. May 2023."},{"key":"1071_CR25","unstructured":"Alexion Pharmaceuticals. Trial of andexanet in patients receiving an oral FXa inhibitor who require urgent surgery (Annexa-S). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04233073. Accessed 15 Feb 2024."},{"issue":"4","key":"1071_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000356","volume":"3","author":"KA Sobolewski","year":"2021","unstructured":"Sobolewski KA, Brophy A, Choi SC, et al. Real-world observational review of andexanet alfa prescribing and utilization outcomes at a community teaching hospital. Crit Care Explor. 2021;3(4): e0356. https:\/\/doi.org\/10.1097\/CCE.0000000000000356.","journal-title":"Crit Care Explor."},{"issue":"16","key":"1071_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/ajhp\/zxac079","volume":"79","author":"J Liu","year":"2022","unstructured":"Liu J, Elsamadisi P, Philips E, et al. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: case series. Am J Health Syst Pharm. 2022;79(16):1323\u20139. https:\/\/doi.org\/10.1093\/ajhp\/zxac079.","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"1071_CR28","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/rth2.12418","volume":"4","author":"G Lu","year":"2020","unstructured":"Lu G, Lin J, Bui K, et al. Andexanet versus prothrombin complex concentrates: differences in reversal of factor Xa inhibitors in in vitro thrombin generation. Res Pract Thromb Haemost. 2020;4(8):1282\u201394. https:\/\/doi.org\/10.1002\/rth2.12418.","journal-title":"Res Pract Thromb Haemost."},{"issue":"Suppl. 1","key":"1071_CR29","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1111\/jth.12949","volume":"13","author":"WH Dzik","year":"2015","unstructured":"Dzik WH. Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal. J Thromb Haemost. 2015;13(Suppl. 1):S187\u201394. https:\/\/doi.org\/10.1111\/jth.12949.","journal-title":"J Thromb Haemost"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01071-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01071-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01071-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T19:09:57Z","timestamp":1710097797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01071-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01071-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"6 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors received speaker\u2019s honoraria from AstraZeneca. Other than that, the authors have no competing financial interests or personal relationships that could have influenced the work reported in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"The present research complies with the guidelines for human studies, and the research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. This retrospective review of patient data did not require\u00a0ethical approval in accordance with local\/national guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SF and PK were responsible for the conception and design of the study. All authors were involved in the data acquisition, interpretation, drafting, and review of the article as well as its final approval.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}